Author name: Leonardo Arias

The move builds on the major PBM’s pivot to cost-based pricing for pharmacies announced earlier this year.

The companies will develop a robotic system to improve patient outcomes in complex hemorrhagic cases and time-sensitive ischemic strokes.

Moving forward, Innate will focus on the clinical development of its antibody-drug conjugate IPH4502, the lymphoma candidate lacutamab and the AstraZeneca-partnered monalizumab.

The New York-based provider said it’s cutting less than 2% of staff as it contends with rising expenses.

In letters to Eli Lilly and Novo Nordisk, the FDA accused the companies of downplaying the risks of their GLP-1 weight loss drugs during a prime time special with Oprah Winfrey.

The continuing resolution would fund the government, and preserve the flexibilities, through Nov. 21. But the bill makes no mention of extending more generous financial assistance for people who buy plans on the exchanges.

The continuing resolution would fund the government, and preserve the flexibilities, through Nov. 21. But the bill makes no mention of extending more generous financial assistance for people who buy plans on the exchanges.

A complex state vs. federal regulatory scheme allows drug compounders to advertise drugs without disclosing risks like a pharma company must do. Experts say it’s time for the FDA to crack down.

America’s primary care chassis is crumbling. How Medicare pays physicians is partially to blame. But expanding value-based payment arrangements could be the answer, experts say.

The over-representation of males and Hispanic patients in Eli Lilly’s Phase III ATTAIN-1 study could explain why orforglipron “underperformed” expectations in a previous readout, according to analysts at BMO Capital Markets.